For effective adoptive immunotherapy of cancer, tumor-specific T lymphocytes must be obtained from tumor-bearing patients, activated in vitro and expanded to large numbers, but tumor-induced suppressor cells and the unavailability of tumor antigen may critically limit the expansion of tumor-reactive T cells. In murine tumor models, we have found that T cells from tumor-draining lymph nodes (DLN) are more readily expanded than spleen cells from the same hosts, and that these cells have therapeutic activity in vivo. Low dose cyclophosphamide in vivo and an analogue (mafosfamide) used in vitro can inhibit the ability of suppressor cells to limit cytotoxic T lymphocyte (CTL) growth, without adversely affecting CTL activation. CTL from syngeneic murine P815 tumor-bearing host (TBH) spleens, which would otherwise not grow, could be expanded after in vitro treatment with mafosfamide. Using pharmacologic manipulation of the pathways of T cell signal transduction, via activation of protein kinase C and increasing intracellular Ca++, in place of antigen we could expand T cells which were cytotoxic in vitro and therapeutic in vivo. We have also derived tumor-specific CTL clones from TBH mice which not only depend upon both antigen and exogenous interleukin 2 (IL-2) for growth, but also can attain a """"""""resting"""""""" state similar to memory CTL from TBHS. From this resting state, we can distinctly separate the antigen-dependent and IL-2- dependent stages of T cell activation. Thus, we have a unique opportunity to examine in detail the regulation of T cell activation in a tumor- specific, non-transformed and regulable CTL clone. These cloned CTL also have therapeutic activity in vivo and will serve as a model on which to base rational manipulations of lymphocytes from TBH which will maximize T cell growth and preserve anti-tumor activity. Moreover, the above methods of suppressor cell inhibition and pharmacologic T cell activation are applicable to DLN from human patients with breast cancer, but the responsiveness of cells from individual nodes is highly variable. This project aims to: (1) Determine how different methods of T cell activation can be used to expand CTL clones and to delineate the detailed cellular and molecular mechanisms by which regulatory cytokines (IL-2, IL-4 and TGF-Beta) affect the growth of cloned CTL; (2) Determine whether similar methods, combined with inhibition of Ts, function by mafosfamide, can be applied to the expansion of bulk cultures of T cells obtained directly from TBH mice, so that the yield of cells is maximized and anti- tumor activity is maintained; (3) Test the T cells obtained by different, strategies of expansion for therapeutic efficacy in vivo; and (4) Determine how to identify, isolate and expand T cells with potential anti- tumor activity from the DLN of human breast cancer patients, using similar strategies, including mafosfamide treatment and pharmacologic activation of T cells. The proposed studies should lead to a clearer. understanding of tumor-specific CTL activation, regulation and growth and to more rational and more effective strategies for clinical adoptive immunotherapy of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA048075-05
Application #
3192026
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1988-08-15
Project End
1994-08-31
Budget Start
1992-09-01
Budget End
1993-08-31
Support Year
5
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Miller, Catriona H T; Graham, Laura; Bear, Harry D (2010) Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma. BMC Immunol 11:54
Chin, Cynthia S; Miller, Catriona H T; Graham, Laura et al. (2004) Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes. Int Immunol 16:1283-94
Parviz, Maryam; Chin, Cynthia S; Graham, Laura J et al. (2003) Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunol Immunother 52:739-50
Chin, Cynthia S; Bear, Harry D (2002) Sentinel node mapping identifies vaccine-draining lymph nodes with tumor-specific immunological activity. Ann Surg Oncol 9:94-103
Chin, C S; Graham, L J; Hamad, G G et al. (2001) Bryostatin/ionomycin-activated T cells mediate regression of established tumors. J Surg Res 98:108-15
Kos, F J; Cornell, D L; Lipke, A B et al. (2000) Protective role of IL-2 during activation of T cells with bryostatin 1. Int J Immunopharmacol 22:645-52
Kos, F J; Bear, H D (1998) Involvement of protein kinase C-delta in CD28-triggered cytotoxicity mediated by a human leukaemic cell line YT. Immunology 94:575-9
Baldwin, N G; Rice, C D; Tuttle, T M et al. (1997) Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes. J Neurooncol 32:19-28
Rice, C D; Baldwin, N G; Biron, R T et al. (1997) Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes. J Neurooncol 32:29-38
Merchant, R E; Baldwin, N G; Rice, C D et al. (1997) Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Neurol Res 19:145-52

Showing the most recent 10 out of 31 publications